FLT3 tyrosine kinase in acute non-lymphoblastic leukemias

FLT3 tyrosine kinase in acute non-lymphoblastic leukemias

.

Saved in:

Bibliographic Details
Main Authors:	A. S. Bavykin, M. A. Volkova
Format:	Article
Language:	Russian
Published:	ABV-press 2022-11-01
Series:	Онкогематология
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/647
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
by: Ariadne Malamitsi-Puchner, et al.
Published: (2005-01-01)

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study
by: Matteo Dragani, et al.
Published: (2025-01-01)

TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)
by: K. I. Zarubina, et al.
Published: (2017-10-01)

Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors
by: Nawin Manachai, et al.
Published: (2022-01-01)

It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosin kinase inhibitor therapy
by: Jan J. Cornelissen, et al.
Published: (2025-05-01)

FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE
by: Ghaleb Elyamany, et al.
Published: (2014-05-01)

Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Jung Min Lee, et al.
Published: (2025-01-01)

FLT3-ITD POSITIVE ACUTE MYELOİD LEUKEMIA MIMICKING ACUTE PROMYELOCYTIC LEUKEMİA
by: Birsen Sahip Yesiralioğlu, et al.
Published: (2024-12-01)

Tyrosine Kinase Inhibitor Post-Allogeneic Stem Cell Transplantation in Adult Philadelphia-Positive B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
by: Martina Canichella, et al.
Published: (2025-02-01)

RSK1 dependency in FLT3-ITD acute myeloid leukemia
by: Tim Kong, et al.
Published: (2024-11-01)

Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
by: Hema Dave, et al.
Published: (2012-01-01)

Acute lymphoblastic leukemia in children
by: M. A. Maschan, et al.
Published: (2022-11-01)

FLT3 inhibition upregulates OCT4/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-03-01)

Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01)

Characterization of the FLT3 Mutation in Newly Diagnosed Patients with Acute Myeloid Leukemia
by: Luay Fahad, et al.
Published: (2024-06-01)

Acute lymphoblastic leukemia in infants
by: Aytemiz Gürgey, et al.
Published: (2004-04-01)

Hypomethylation of the Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Gene Promoter Region and Elevated sFlt-1 Placental Expression as Risk Factors for Preeclampsia
by: Anak Agung Ngurah Jaya Kusuma, et al.
Published: (2025-08-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Acute lymphoblastic leukemia and toxoplasmosis
by: G Hiçsönmez, et al.
Published: (1979-01-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
by: IL Davydkin, et al.
Published: (2018-10-01)

The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data
by: Matthew Schwede, et al.
Published: (2025-02-01)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
by: Stephen E. Langabeer, et al.
Published: (2020-01-01)

Immunophenotypic investigation of infant acute lymphoblastic leukemia
by: A. M. Popov, et al.
Published: (2014-07-01)

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
by: Andrew D. Hughes, et al.
Published: (2025-01-01)

COVID-19 in patients with acute lymphoblastic leukemia
by: T. S. Chudnova, et al.
Published: (2024-09-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-03-01)

Features of children temperament with acute lymphoblastic leukemia
by: N. A. Kornetov, et al.
Published: (2016-02-01)

Acute non-lymphoblastic leukemia: characteristics of cytogenetic anomalies and their influence on clinical course of the disease
by: A. M. Vakulchuk, et al.
Published: (2022-11-01)

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
by: Adam S Kittai, et al.
Published: (2025-01-01)

Hemostasis defects correction in children with acute lymphoblastic leukemia
by: A. S. Roshik, et al.
Published: (2022-11-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

THE HISTORY OF CHRONIC MYELOID LEUKEMIA (CML): FROM ARSENIC TO TYROSINE KINASE INHIBITORS (TKI)
by: Rüdiger Hehlmann
Published: (2025-07-01)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
by: Daniel Medina-Gil, et al.
Published: (2025-03-01)

MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
by: Ibrahim C. Haznedaroglu
Published: (2013-12-01)

Neddylation status determines the therapeutic sensitivity of tyrosine kinase inhibitors in chronic myeloid leukemia
by: Congyi Zhang, et al.
Published: (2025-05-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Prethymic Cytoplasmic CD3 Negative Acute Lymphoblastic Leukemia or Acute Undifferentiated Leukemia: A Case Report
by: Elisa Cannizzo, et al.
Published: (2011-01-01)

Blinatumomab in pediatric B-acute lymphoblastic leukemia
by: Yifang Cheng, et al.
Published: (2025-07-01)